# Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients

> **NCT04817774** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sangamo Therapeutics** · enrollment: 26 (actual)

## Conditions studied

- Kidney Transplant Rejection
- End Stage Renal Disease

## Interventions

- **BIOLOGICAL:** TX200-TR101

## Key facts

- **NCT ID:** NCT04817774
- **Lead sponsor:** Sangamo Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-17
- **Primary completion:** 2024-07-11
- **Final completion:** 2025-10-29
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04817774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04817774, "Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04817774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*